About Neditol 2018-05-10T12:58:36+00:00





Welcome to neditol.co.uk

Neditol? XL is a prolonged-release capsule of tolterodine tartrate indicated in symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.1

Available as:

  • 4mg?prolonged-release capsules
  • 2mg prolonged-release capsules (available for the first time in the UK)

Neditol XL is bioequivalent?to Detrusitol? XL (Pfizer Limited, Surrey, UK).2

Neditol XL offers significant savings to your practice and?clinical commissioning group (CCG).

Typically generic products are listed in category M of the UK Drug Tariff. On patent expiry of the originator product, the market price then declines significantly and savings?are eventually passed on to the practice or CCG.

However, category C Drug Tariff products are often more difficult to manufacture and their reimbursed price remains the same whether it be an originator product or generic. Tolterodine 4mg prolonged-release capsules are in category C of the Drug Tariff.3

Neditol XL is different as Aspire Pharma have priced the product with the Department of Health to give your practice or CCG savings of up to 50%?on the cost of the Category C Drug Tariff price for?tolterodine 4mg prolonged-release capsules when Neditol XL is prescribed by brand.3*

At CCG level, the average cost of tolterodine XL prescribing is >£160,000. A change to Neditol XL would result in prescribing savings >£80,100.4**

In addition to making 50% cost savings,* Neditol XL:
? Available from mainline wholesalers;
? High level of stockholdings;
? Price guaranteed till 2019;***
? Bioequivalent to the originator brand;2
? Additional 2mg strength.

References: *50% saving on the cost of Category C tolterodine 4mg prolonged-release tablets in the UK Drug Tariff. **Based on the data in reference 4 for 211 CCGs switching their tolterodine prolonged-release tablets prescriptions to Neditol XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2019 PPRS review, regardless of competitor activity.
References 1) Neditol XL SmPCs. 2) Data on file. 1010067149 v 1.0 June 2016. 3) February 2017 UK Drug Tariff. 4) IMS Health BPI Data September 2013 – August 2014.

For further information please call: 01730 231148, email: info@www.soyporteno.com or visit www.www.soyporteno.com

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
For more information about Neditol XL, please see the abbreviated prescribing information.
Revision reference – Neditol XL_16__27/02/2017